In our study we analyzed the effects of the three currently available Syk inhibitors, Piceatannol, Bay-61-3606 and R406 on the viability and functional properties of myeloma cells in order to provide a mechanistic understanding and a rationale for a possible use of these compounds as therapeutic option. The gene discussed is SYK; the disease is plasma cell myeloma.